Biologic Function

Recent Advances in AI & Multi-Omics for Translational Research

2 weeks ago talkbio0Tagged agentic AI, AI-driven, Biological Markers, Cancer Research, Discover, DNA Integration, drug response, Machine Learning, Multiomics, Precision Medicine, Prediction, Stratification, Study models, Translational Research, Biomedical

AI-driven multi-omics integration; translational research; precision medicine; biomarker discovery; patient stratification; machine learning; foundation models; agentic AI; cancer research; drug response prediction

Researchers Advance Toward Matching Patients with the Most Effective GLP-1 Drug for Personalized Obesity Treatment

3 weeks ago talkbio0Tagged aspects of adverse effects, drug response, Genetic screening method, Glucagon-Like Peptide 1, Machine Learning, Mayo Clinic, MyPhenome, Obesity, personalized care, Precision Medicine, Prediction, Treatment Adherence

GLP-1; precision medicine; obesity; drug response prediction; genetic test; personalized care; side effects; machine learning; MyPhenome; Mayo Clinic; treatment adherence

Argenx’s Vyvgart Shows Positive Phase 3 Results in Seronegative Myasthenia Gravis

4 months ago talkbio0Tagged AChR-Ab, Adaptation, Argenx, expansion, Labels (device), LRP4 gene, Musk, Myasthenia Gravis, Phase 3, SERON, Seronegative, triple seronegative, United States Food and Drug Administration, Vyvgart

Vyvgart; Argenx; Phase 3; myasthenia gravis; seronegative; ADAPT SERON; AChR-Ab; MuSK+; LRP4+; triple seronegative; FDA label expansion

Novavax Approval Process Raises Concerns Among Former Regulators About FDA Integrity

6 months ago talkbio0Tagged Approved, concerns, COVID19 (disease), delays, Intact, Interferes with, Novavax, political, Regulation of biological process, United States Food and Drug Administration, Vaccines

Novavax; FDA approval; COVID-19 vaccine; regulatory process; integrity concerns; delays; political interference

Sanofi Licenses Formation Bio’s JAK/SYK Inhibitor Gusacitinib in $630M+ AI-Driven Deal

6 months ago talkbio0Tagged AI drug development, Anabolism, Bio, chronic hand eczema, gusacitinib, Indication of (contextual qualifier), JAK/SYK inhibitor, Libertas Bio, licensing agreement, sanofi

Sanofi; Formation Bio; gusacitinib; JAK/SYK inhibitor; AI drug development; Libertas Bio; deal; chronic hand eczema; new indication; licensing agreement

Medtronic’s PillCam Genius SB Completes First Patient Procedure for GI Diagnostics

12 months ago talkbio0Tagged antimony, Capsule Endoscopy, Diagnostics, gastroenterology (field), Ingestion, Medtronic, PillCam Genius, Telemedicine

Medtronic, PillCam Genius SB, Capsule Endoscopy, GI Diagnostics, At-Home Ingestion, Telehealth

MeiraGTx’s Gene Therapy Shows Significant Improvements in Motor Function and Quality of Life in Parkinson’s Disease Trial

1 year ago talkbio0Tagged AAV-GAD, Clinical Trials, dopamine, gamma-aminobutyric acid, gene therapy, MeiraGTx, Motor function (observable entity), Neurodegenerative Disorders, Parkinson 's disease, Phase 2 trial, production, Quality of life, Surgical Replantation

MeiraGTx, Gene Therapy, Parkinson’s Disease, AAV-GAD, Motor Function, Quality of Life, Clinical Trial, Phase 2 Trial, Neurodegenerative Disease, Dopamine Replacement, GABA Production

Biogen’s Higher Dose Spinraza Shows Enhanced Efficacy in Treating Spinal Muscular Atrophy

1 year ago talkbio0Tagged Biogen, Clinical Trials, DEVOTE, Dose Regimen, High, Improvement, Motor function (observable entity), Nerve Degeneration, nusinersen, Spinal Muscular Atrophy, Spinraza

Biogen, Spinraza, Nusinersen, Spinal Muscular Atrophy (SMA), Higher Dose Regimen, Clinical Trial Results, DEVOTE Study, Motor Function Improvement, Neurodegeneration Reduction

Scholar Rock’s Apitegromab Shows Significant Improvement in Spinal Muscular Atrophy Treatment

1 year ago talkbio0Tagged apitegromab, Clinical Trials, GDF8 protein, human, Improvement, Motor function (observable entity), Phase 3, Psychological inhibition, Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA), Apitegromab, Phase 3 Clinical Trial, Motor Function Improvement, Myostatin Inhibition

Can Element Biosciences Challenge Illumina in the DNA Sequencing Market?

1 year ago talkbio0Tagged ABC, Anabolism, Avidity Base Chemistry, Aviti sequencer, Biotechnology, Cloudbreak, competition, DNA Sequence, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Market, SBS, Sequence Analysis

Element Biosciences, Illumina, DNA sequencing, next-generation sequencing (NGS), Avidity Base Chemistry (ABC), sequencing by synthesis (SBS), Cloudbreak, Aviti sequencer, genomics, biotechnology, market competition